glp-1 drugs with least side effects GI Adverse of Glucagon-Like Peptide-1 Receptor Agonists Mapping the effectiveness and risks

Patients experience abnormal stomach movement that lasts at least three months

[DOI] [PMC free article] [PubMed] [Google Scholar] 37.Kamrul-Hasan ABM, Alam MS, Dutta D, Sasikanth T, Aalpona FTZ, Nagendra L

Some people experience unpleasant side effects (e.g., nausea, constipation) that do not resolve over time, preventing its continued use

Endocrinology 157: 45614569

are former employees and shareholders of AstraZeneca UK Limited

Furthermore, the secretome of hMSC-Ex-4 displayed an altered protein profile, including enhanced secretion of insulin-like growth factorbinding protein 2 (IGFBP2) and apolipoprotein M (APOM), both of which are implicated in metabolic regulation and may contribute to the therapeutic modulation of type 2 diabetes mellitus [18]